Press Release
4C Medical's AltaValve System Commences Pivotal Trial Enrollment
MINNEAPOLIS, Oct. 8, 2024 /PRNewswire/ -- 4C Medical Technologies, Inc. ("4C Medical"), a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, has commenced enrollment in the ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) trial in Europe and United States. ATLAS is a pivotal trial that is designed to assess the safety and efficacy performance of its AltaValve™ System in treating patients with moderate-to-severe or severe mitral regurgitation (MR) who are unsuitable for surgery or transcatheter edge-to-edge repair (NCT06465745).
4C Medical Technologies Presents Data from the Global Clinical Experience for the AltaValve Early Feasibility Study at AATS 2022
MINNEAPOLIS, May 19, 2022 - 4C Medical Technologies, Inc. ("4C Medical" or the "Company"), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, presented its global clinical experience from its initial AltaValve Early Feasibility Study (EFS) cases at the American Association for Thoracic Surgery (AATS) 2022 Mitral Conclave Workshop on May 13, 2022 in Boston, MA.
MINNEAPOLIS, MN, March 31, 2022 – 4C Medical Technologies, Inc. (“4C Medical” or the “Company”), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, announced that it has completed a $35.4 million Series C Preferred Stock financing. The Series C round was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).
AltaValve™, 4C Medical's Novel Transcatheter Mitral Regurgitation Device Highlighted at TCT 2019
MAPLE GROVE, Minn., Sept. 30, 2019 /PRNewswire/ -- 4C Medical Technologies, Inc., the creator of a new generation of therapies for structural heart disease, announced today that its medical device therapy for mitral regurgitation (MR), AltaValve™, was featured at Transcatheter Cardiovascular Therapeutics (TCT) 2019, on Sept 25-29 in San Francisco, CA.
4C Medical's Novel Mitral Regurgitation Therapy to be Highlighted at CRT 2019 Meeting
BROOKLYN PARK, Minn., Feb. 25, 2019 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a transcatheter mitral valve replacement (TMVR) technology, will be highlighted in the following presentations at the Cardiovascular Research Technologies (CRT) meeting held March 2-5, 2019 in Washington, DC.
4C Medical Technologies Announces $17 Million Series A Financing
MINNEAPOLIS, Minn. — September 10, 2018 – 4C Medical Technologies, Inc. (4C Medical), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, today announced that it completed a private placement of shares of its Series A Preferred Stock last week, resulting in total gross proceeds of approximately $17 million.
4C Medical’s AltaValve First In Human Experience to be Presented at TCT 2018
Brooklyn Park, Minn. – September 13, 2018 – 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its AltaValve™, a transcatheter mitral valve replacement (TMVR) technology, will be highlighted in the following presentations at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 21-25, 2018 in San Diego, CA
4C Medical Advances the State of the Heart
Brooklyn Park, Minn. – 29-Jun-2018 - 4C Medical Technologies, Inc. (4C Medical), named after the four chambers of the heart, is developing a novel, minimally invasive device for the treatment of mitral regurgitation (MR). MR impacts up to 10 percent of people over age 75, half of whom are not eligible for open-heart surgery. The need for a minimally invasive solution and the growing addressable population have driven both increased investment and innovation in minimally invasive solutions.
BROOKLYN PARK, Minn., March 7, 2018 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that AltaValve™, its medical device for mitral regurgitation (MR), was awarded first place in the Cardiovascular Research Technologies (CRT) competition held March 3-6, 2018 in Washington, DC.
BROOKLYN PARK, Minn., Dec. 5, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) was awarded the Best Technology Parade Presentation at the International Conference for Innovations in Cardiovascular Interventions (ICI) held December 3-5, 2017 in Tel Aviv, Israel.
4C Medical's Novel Transcatheter Mitral Valve Presented at TCT 2017 Shark Tank Innovation Competition
BROOKLYN PARK, Minn., Nov. 2, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive technologies for structural heart disease, today announced that its medical device for mitral regurgitation (MR) was presented at the Shark Tank Innovation Competition at the Transcatheter Cardiovascular Therapeutics (TCT) meeting held October 29-November 2, 2017 in Denver, CO. The device was one of the eight innovations selected among nearly fifty submissions.
4C Medical's Novel Mitral Regurgitation Therapy Highlighted at CVI 2017 Innovation Summit
BROOKLYN PARK, Minn., Aug. 3, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a developer of minimally invasive therapies for structural heart disease, today announced that its medical device therapy for mitral regurgitation (MR) was featured in the Innovation Summit at Cardiovascular Innovations (CVI) 2017 held August 2, 2017in Denver, CO.
CEOCFO Magazine Interview
July 31, 2017 — Medical Device Therapy for Mitral Regurgitation (MR) that Eliminates Placement and Fixation Problems Associated with Conventional Transcatheter Mitral Valve Replacement Technologies
Interview conducted by: Lynn Fosse, Senior Editor CEOCFO Magazine, Published – July 31, 2017
4C Medical Exceeds $8 Million Convertible Note Financing Round Led by Anges Québe
BROOKLYN PARK, Minn., July 19, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc. (4C Medical), a medical technology company focused on the development of minimally invasive therapies for structural heart disease, today announced it has completed a private placement of unsecured convertible promissory notes resulting in gross proceeds to the company of approximately $9 million. 4C Medical intends to use the proceeds from the financing to fund the continued development of its transcatheter technology for the treatment of mitral regurgitation (MR). The financing was led by an investment of $3.5 million by Anges Québec, the largest angel network in Canada.
Start-Up Spotlight: 4C Addresses Mitral Regurgitation With Unique 'Dome' Device
29 Jun 2017 - US firm 4C Medical Technologies is developing a unique solution to mitral regurgitation that sits outside the valve and takes advantage of the native valve's remaining function while preventing mitral regurgitation. The Minnesota-based start-up is currently funded by angel investors and "friends and family," but expects to raise a $15m Series B round in early 2018.
4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum
BROOKLYN PARK, Minn., June 15, 2017 /PRNewswire/ -- 4C Medical Technologies, Inc., a developer of minimally invasive therapies for structural heart disease, today announced that its medical device therapy for mitral regurgitation (MR) was featured in the Transcatheter Valve Therapies (TVT) Innovation Forum which took place June 14, 2017 in Chicago, IL. The company is developing the first MR therapy that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The novel design eliminates known issues of current transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle.